News

They have a knack for increasing their dividends even when facing challenges.

I'd buy Energy Transfer and Verizon stocks, and avoid Pfizer.

IP Group PLC (FRA:IOOA) grew NAV per share to 114p and generated GBP69 million in H1 2026 cash proceeds, more than doubling last year's first-half total.

Key Stats for PFE StockPast week performance: Consolidating52-week range: $24 to $29Valuation model target price: $28Implied upside: 2. 8% over 2.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and...

A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.

PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.

Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.

Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon?

Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.

Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.

The company is coming back into the spotlight thanks to recent developments.

Patient investors who buy the stock may be rewarded over the long term.

Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.

Pfizer gained on vaccine and oncology growth, MiniMed on strong earnings, and Deere on AI-driven agriculture.

Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make.

The signs were not in the headline growth rate but in which two products were trading places.

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

These are two stocks that pay investors a regular income.

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.

MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.